Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 16/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903370 | 0.91 | SYK (0.59) | JAK2HDAC1HDAC6SYKADORA2A | |
| SCHEMBL4892505 | 0.88 | ABL1 (0.57) | SYKADORA2AADORA1 | |
| SCHEMBL4899494 | 0.88 | SYK (0.57) | JAK2HDAC1HDAC6SYK | |
| SCHEMBL4903418 | 0.87 | ALDH1A1 (0.59) | JAK2HDAC1HDAC6SYK | |
| SCHEMBL4905329 | 0.85 | JAK2 (0.68) | JAK2HDAC1HDAC6SYKMET | |
| SCHEMBL4901557 | 0.83 | ABL1 (0.66) | JAK2SYK | |
| SCHEMBL4903752 | 0.83 | PTK2 (0.56) | JAK2HDAC1HDAC6SYK | |
| SCHEMBL4901743 | 0.81 | JAK2 (0.54) | JAK2HDAC1HDAC6SYK | |
| SCHEMBL4903833 | 0.80 | SYK (0.57) | JAK2SYKMET | |
| SCHEMBL4900241 | 0.79 | SYK (0.53) | JAK2HDAC1HDAC6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | JAK2 1695/4885HDAC1 4522/4885HDAC6 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.